Home › NCT07413666

A Study of ORX489 in Healthy Adult Participants, Aged 18 to 60 Years

A Safety, Tolerability, Pharmacokinetic, Food Effect, and Proof-of-Concept Study of Single and Multiple Doses of ORX489 in Healthy Adults

Who can join

Ages 18 to 60 · All sexes · Healthy volunteers welcome

Inclusion Criteria:

* Healthy males or females as determined by assessments at the Screening Visit.
* For Parts A, B, C, and D: Participants must be at least 18 years of age and no more than 60 years of age at the Screening

Exclusion Criteria:

* Presence of significant cardiac, pulmonary, gastrointestinal, hepatic, renal, hematological, malignancy, endocrine, neurological, or psychiatric disease, as determined by medical history, physical examination, and screening investigations.
* History of seizure disorder, any other condition that increases the risk of seizure
* Has a clinically significant sleep disorder, including insomnia or sleep apnea

About the study

Characterize the safety, tolerability and pharmacokinetics of ORX489 following single and multiple doses.

What is being tested

• ORX489 Tablets (drug)
• Placebo Tablets (other)

Sponsor: Centessa Pharmaceuticals (UK) Limited · Participants: 212 · Started: Feb 25, 2026

Contact the study team

• ORX489 Centessa Program Lead ORX489 Centessa Program Lead · Phone: 617-468-5770

Official record on ClinicalTrials.gov — NCT07413666

Locations in the U.S.

From ClinicalTrials.gov, data retrieved Sep 30, 2026. Each study sets its own eligibility; the study team decides who can join.